Arcellx Inc (ACLX) Growth Rates Comparisons to Biotechnology & Pharmaceuticals Industry, Sector, Market. Sales, Income, EPS
CSIMarket
 
Arcellx Inc   (NASDAQ: ACLX)
 

Arcellx Inc Growth Comparisons

Select each growth Category to receive further Information





ACLX Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q4 MRQ) -89.17 % 7.78 % 8.07 % 9.17 %
Q / Q Revenue Growth (Q4 MRQ) -66.58 % 3.44 % 1.81 % 4.22 %
Y / Y Revenue Growth (for 12 months ending Q4 TTM) -79.35 % 10.53 % 7.04 % %
Sequential Revenue Growth (for 12 months ending Q4 TTM) -37.92 % 6.05 % 3.51 % 2.08 %
Revenue 5 Year Average Growth - 8.2 % 8.65 % 10.59 %


ACLX's Growth Comparisons in IV. Quarter 2025




As Arcellx Inc 's sales faded by -89.17% year on year in the fourth quarter 2025, the Biotechnology & Pharmaceuticals industry grew by 7.78%, Arcellx Inc 's fourth quarter 2025 performance was trailing the Biotechnology & Pharmaceuticals industry in the fourth quarter 2025, and underperformed the 8.07% Revenue growth in the Healthcare sector. Weak fourth quarter sales, in Biotechnology & Pharmaceuticals industry and within the Healthcare sector, were reflected in Arcellx Inc results which underperformed overall market.

Top-line fell by -66.58% from the third quarter results. Comparing the annual growth, sales of % on average in last five years, to the S & P 500's, including only Businesses with the fourth quarter 2025 financial results, average yearly sales growth is 10.59%. Arcellx Inc grew less than the market.

ACLX Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
Total
-80.99 %
-34.49 %


Growth Rates of ACLX's Income in the fourth quarter 2025


ACLX Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q4 MRQ) - 64.58 % 27.58 % 29.95 %
Sequential Operating Income Change (Q4 MRQ) - -0.43 % -17.34 % 4.5 %
Y / Y Operating Income Growth (Q4 TTM) - - 37.03 % 14.37 %
Sequential Operating Income Growth (Q4 TTM) - 51.65 % 9.74 % 6.96 %
Operating Income 5 Year Avg. Change - -18.41 % 10.39 % 18.76 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q4 MRQ) - - - 21.83 %
Sequential Income from Cont. Ops. Change (Q4 MRQ) - - - 11.13 %
Y / Y Income from Cont. Ops. Change (Q4 TTM) - - -25.13 % 16.46 %
Sequential Income from Cont. Ops. Change (Q4 TTM) - -81.87 % -6.43 % 6.05 %
Income from Cont. Ops. 5 Year Avg. Change - -11.5 % 0.17 % -28.52 %

ACLX Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q4 MRQ) - - 16.75 % 21.56 %
Q / Q Net Income Growth (Q4 MRQ) - -57.17 % -34.6 % 11.12 %
Y / Y Net Income Change (Q4 TTM) - - 32.74 % 16.59 %
Sequential Net Income Change (Q4 TTM) - 32.44 % 7.31 % 6.03 %
Net Income 5 Year Avg. Growth - -8.55 % 9.21 % 22.96 %

ACLX's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q4 MRQ) - - - 21.83 %
Sequential EPS from Cont. Ops. Change (Q4 MRQ) - - - 11.13 %
Y / Y EPS from Cont. Ops. Change (Q4 TTM) - - - -
Sequential EPS from Cont. Ops. Change (Q4 TTM) - - - -99.7 %
EPS from Cont. Ops. 5 Year Avg. Growth - 49.32 % 0.17 % -28.52 %



ACLX EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q4 MRQ) - - 16.75 % -28.52 %
Q / Q EPS Net Growth (Q4 MRQ) - -57.32 % -34.6 % 11.12 %
Y / Y EPS Net Change (for 12 months ending Q4 TTM) - - - -99.97 %
Sequential EPS Net Change (for 12 months ending Q4 TTM) - - - -99.87 %
EPS Net 5 Year Avg. Change - -8.55 % 9.21 % 22.96 %



Arcellx Inc reported bottom-line of $ -1.03 in the fourth quarter, compare to $ -0.88 in the same quarter a year ago. Biotechnology & Pharmaceuticals industry grew by 7.78%, while Healthcare sector increased by 16.75%, and overall market improved by 21.56%.

Bottom-line fell by -66.58% from the third quarter results. Comparing the annual growth, income per share of % on average in last five years, to the S & P 500's, including only Businesses with the fourth quarter 2025 earnings, average yearly income per share growth is 22.96%. Arcellx Inc grew less than the market.

ACLX Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q4 MRQ) - -28.32 % -10.43 % 2 %
Sequential Free Cash Flow Change (Q4 MRQ) - -31.91 % -28.82 % 22.32 %
Y / Y Free Cash Flow Change (Q4 TTM) - 2.86 % 11.09 % 11.81 %
Sequential Free Cash Flow Change (Q4 TTM) - -5.02 % 1.93 % 2.41 %
Free Cash Flow 5 Year Avg. Change - -14.51 % 0.92 % 8.28 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q4 MRQ) - -80.06 % -90.24 % 1035.72 %
Sequential Net Cash Flow Change (Q4 MRQ) -92.55 % -64.86 % -99.01 % -
Y / Y Net Cash Flow Change (Q4 TTM) - -50.97 % -23.28 % -
Sequential Net Cash Flow Change (Q4 TTM) - -48.01 % -25.11 % -
Net Cash Flow 5 Year Avg. Change - 23.25 % 6.46 % 1.06 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q4 MRQ) -49.03 % -14.5 % 9.45 % 23.41 %
Sequential Capital Expenditures Change (Q4 MRQ) 158.11 % 38.91 % 18.78 % 18.97 %
Y / Y Capital Expenditures Change (Q4 TTM) -82.68 % -14.15 % 10.57 % 23.88 %
Sequential Capital Expenditures Change (Q4 TTM) -24 % -9.75 % 6.56 % 7.02 %
Capital Expenditures 5 Year Avg. Change - 9.64 % 9.18 % 14.72 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 







Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.